Melatonin is protective in necrotic but not in caspase-dependent, free radical-independent apoptotic neuronal cell death in primary neuronal cultures.
To assess the neuroprotective potential of melatonin in apoptotic neuronal cell death, we investigated the efficacy of melatonin in serum-free primary neuronal cultures of rat cortex by using three different models of caspase-dependent apoptotic, excitotoxin-independent neurodegeneration and compared it to that in necrotic neuronal damage. Neuronal apoptosis was induced by either staurosporine or the neurotoxin ethylcholine aziridinium (AF64A) with a delayed occurrence of apoptotic cell death (within 72 h). The apoptotic component of oxygen-glucose deprivation (OGD) unmasked by glutamate antagonists served as a third model. As a model for necrotic cell death, OGD was applied. Neuronal injury was quantified by LDH release and loss of metabolic activity. Although melatonin (0.5 mM) partly protected cortical neurons from OGD-induced necrosis, as measured by a significant reduction in LDH release, it was not effective in all three models of apoptotic cell death. In contrast, exaggeration of neuronal damage by melatonin was observed in native cultures as well as after induction of apoptosis. The present data suggest that the neuroprotectiveness of melatonin strongly depends on the model of neuronal cell death applied. As demonstrated in three different models of neuronal apoptosis, the progression of the apoptotic type of neuronal cell death cannot be withhold or is even exaggerated by melatonin, in contrast to its beneficial effect in the necrotic type of cell death.
Harms
C
C
Institute of Pharmacology and Toxicology, Medical Faculty Charité, Humboldt-University Berlin, D-10098 Berlin, Germany.
Lautenschlager
M
M
Bergk
A
A
Freyer
D
D
Weih
M
M
Dirnagl
U
U
Weber
J R
JR
Hörtnagl
H
H
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis; D001388:Aziridines; D061945:Caspase Inhibitors; D020169:Caspases / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002794:Choline / Q000031:analogs & derivatives*; D003497:Cyclic N-Oxides; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016166:Free Radical Scavengers / Q000494:pharmacology; D005609:Free Radicals / Q000378:metabolism; D005947:Glucose / Q000172:deficiency / Q000378:metabolism; D000860:Hypoxia / Q000378:metabolism; D008550:Melatonin / Q000494:pharmacology*; D009336:Necrosis; D009474:Neurons / Q000187:drug effects* / Q000473:pathology; D009589:Nitrogen Oxides / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D019311:Staurosporine / Q000494:pharmacology; D013890:Thiourea / Q000031:analogs & derivatives* / Q000494:pharmacology
D000975:Antioxidants; D001388:Aziridines; D061945:Caspase Inhibitors; D003497:Cyclic N-Oxides; D004791:Enzyme Inhibitors; D016166:Free Radical Scavengers; D005609:Free Radicals; D009589:Nitrogen Oxides; C029217:phenyl-N-tert-butylnitrone; C038983:1,3-dimethylthiourea; C044894:ethylcholine aziridinium; D020169:Caspases; D013890:Thiourea; D019311:Staurosporine; D005947:Glucose; D008550:Melatonin; D002794:Choline